Forbes: Nate Pile's 2017 Top Recommendations: Mnkd
Dec 27, 2016 15:09:12 GMT -5
via mobile
afrezzamiracle, sportsrancho, and 10 more like this
Post by lakers on Dec 27, 2016 15:09:12 GMT -5
Markets #MarketMoves
12/27/2016 @ 1:42PM 918 Views
Nate Pile's Top Recommendations For 2017
www.google.com/amp/www.forbes.com/sites/kenkam/2016/12/27/nate-piles-top-recommendations-for-2017/
I’ve asked Marketocracy’s managers to tell me what investment strategies and stocks they are talking about with their friends and family at this year’s holiday gatherings. Here’s what Nate Pile is recommending.
Nate Pile is the Founder and Editor of Nates Notes and a Marketocracy member since October 30, 2002. Over the past 14+ years his Marketocracy portfolio returned 18.12% which compares nicely to the S&P500’s 9.06% return for the same period. Over the past 10 years, Nate has outperformed the top U.S. equity mutual fund tracked by Morningstar. Before taking anyone’s investment advice, you should always check out their track record. Here is Nate’s.
Ken Kam: What was your most successful investment this year?
Nate Pile: My most successful investment this year was NVIDEA (NVDA) – from roughly $25 at the beginning of the year to today’s close just over $100 (for the first time ever!). I first recommended the stock in my newsletter at $4.49, and I believe it is a great testament to/validation of my approach.
Kam: What stock are you recommending to your friends and family?
Pile: The stock I am recommending to my friends and family over the holidays is MannKind (MNKD). Though I can’t promise MannKind will have what it takes to get it across the goal line, I am more convinced that ever that Afrezza is on its way to success for two reasons:
a) the final termination and “settlement” with Sanofi greatly improved their odds of success, and
b) with MannKnd currently being valued at less than when it came public (and still had a product in clinical trials rather than an FDA approved product that is proving to be superior to all existing therapies)
I continue to believe that at 60 cents, this is is the sort of opportunity that only comes along once or twice in most investors’ lifetimes.
Kam: MannKind has not done well this year, what do you see happening to turn things around?
Pile: A label change is on the way that will not only help elevate/differentiate the status of Afrezza in the eyes of docs when they first look into it, but it will also make it significantly more difficult for competitors to bully it around on the formularies since it will no longer be in the same class as “regular” insulin.
Kam: What other stocks you are recommending?
Pile: For my relatives who might not be interested in “speculative” biotech, I will be steering them towards Illumina (ILMN) and Walt Disney (DIS) as two “big name, fairly conservative stocks” that they should look into, as well as advise them to buy small lots of gold on a regular basis (i.e. every 4-8 weeks) over the course of 2017. I use the SPDR Gold Trust (GLD) for this in my newsletter, but I actually own gold through the Sprott Physical Gold Trust (PHYS) in my Marketocracy account (and personal accounts as well).
My Take: While Nate does not have a set formula when choosing stocks, the first screen is always done at the fundamental level. For a company to even make it onto his list for consideration, it must have a compelling long-term growth story (be it a new product or a significantly better version of an existing product or service), and its management team must have a clear and sensible business plan against which investors can measure the company’s progress over the years.
When looking at a company from this standpoint, Nate asks himself a question he first saw posed several years ago in a book on Warren Buffet’s investment philosophy, namely “if the stock market closed for five years and we could not trade the stock again until the market re-opened, would we be still be happy buying the stock today?” If the answer is “yes,” then there is a chance the stock will make it into his portfolio.
Generally, speaking, Nate tends to build positions in stocks with a three- to five-year time period in mind, though as long as a company is continuing to execute on its business plan, he is likely maintain at least a partial position in the stock for a much longer period of time. In fact, many of the stocks in Nate’s Marketocracy portfolio have been there since the early 2000s (albeit with some scaling-in and scaling-out along the way in response to changed market conditions).
It is also worth noting that a majority of his picks tend to come from the biotech and high-tech sectors.
12/27/2016 @ 1:42PM 918 Views
Nate Pile's Top Recommendations For 2017
www.google.com/amp/www.forbes.com/sites/kenkam/2016/12/27/nate-piles-top-recommendations-for-2017/
I’ve asked Marketocracy’s managers to tell me what investment strategies and stocks they are talking about with their friends and family at this year’s holiday gatherings. Here’s what Nate Pile is recommending.
Nate Pile is the Founder and Editor of Nates Notes and a Marketocracy member since October 30, 2002. Over the past 14+ years his Marketocracy portfolio returned 18.12% which compares nicely to the S&P500’s 9.06% return for the same period. Over the past 10 years, Nate has outperformed the top U.S. equity mutual fund tracked by Morningstar. Before taking anyone’s investment advice, you should always check out their track record. Here is Nate’s.
Ken Kam: What was your most successful investment this year?
Nate Pile: My most successful investment this year was NVIDEA (NVDA) – from roughly $25 at the beginning of the year to today’s close just over $100 (for the first time ever!). I first recommended the stock in my newsletter at $4.49, and I believe it is a great testament to/validation of my approach.
Kam: What stock are you recommending to your friends and family?
Pile: The stock I am recommending to my friends and family over the holidays is MannKind (MNKD). Though I can’t promise MannKind will have what it takes to get it across the goal line, I am more convinced that ever that Afrezza is on its way to success for two reasons:
a) the final termination and “settlement” with Sanofi greatly improved their odds of success, and
b) with MannKnd currently being valued at less than when it came public (and still had a product in clinical trials rather than an FDA approved product that is proving to be superior to all existing therapies)
I continue to believe that at 60 cents, this is is the sort of opportunity that only comes along once or twice in most investors’ lifetimes.
Kam: MannKind has not done well this year, what do you see happening to turn things around?
Pile: A label change is on the way that will not only help elevate/differentiate the status of Afrezza in the eyes of docs when they first look into it, but it will also make it significantly more difficult for competitors to bully it around on the formularies since it will no longer be in the same class as “regular” insulin.
Kam: What other stocks you are recommending?
Pile: For my relatives who might not be interested in “speculative” biotech, I will be steering them towards Illumina (ILMN) and Walt Disney (DIS) as two “big name, fairly conservative stocks” that they should look into, as well as advise them to buy small lots of gold on a regular basis (i.e. every 4-8 weeks) over the course of 2017. I use the SPDR Gold Trust (GLD) for this in my newsletter, but I actually own gold through the Sprott Physical Gold Trust (PHYS) in my Marketocracy account (and personal accounts as well).
My Take: While Nate does not have a set formula when choosing stocks, the first screen is always done at the fundamental level. For a company to even make it onto his list for consideration, it must have a compelling long-term growth story (be it a new product or a significantly better version of an existing product or service), and its management team must have a clear and sensible business plan against which investors can measure the company’s progress over the years.
When looking at a company from this standpoint, Nate asks himself a question he first saw posed several years ago in a book on Warren Buffet’s investment philosophy, namely “if the stock market closed for five years and we could not trade the stock again until the market re-opened, would we be still be happy buying the stock today?” If the answer is “yes,” then there is a chance the stock will make it into his portfolio.
Generally, speaking, Nate tends to build positions in stocks with a three- to five-year time period in mind, though as long as a company is continuing to execute on its business plan, he is likely maintain at least a partial position in the stock for a much longer period of time. In fact, many of the stocks in Nate’s Marketocracy portfolio have been there since the early 2000s (albeit with some scaling-in and scaling-out along the way in response to changed market conditions).
It is also worth noting that a majority of his picks tend to come from the biotech and high-tech sectors.